Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Nicolas Floc'h"'
Publikováno v:
Ruminate Magazine; Fall2021, Issue 60, p59-66, 8p
Autor:
Jordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, Sara Talbot, Rebecca Whiteley, Nicolas Floc’h, Elizabeth Martínez-Pérez, Matthew J. Martin, Paul D. Smith, Ivana Sullivan, Mikkel G. Terp, Jamal Saeh, Cristina Marino-Buslje, Giulia Fabbri, Grace Guo, Man Xu, Cristian Tornador, Andrés Aguilar-Hernández, Noemí Reguart, Henrik J. Ditzel, Alejandro Martínez-Bueno, Núria Nabau-Moretó, Amaya Gascó, Rafael Rosell, J. Elizabeth Pease, Urszula M. Polanska, Jon Travers, Jelena Urosevic, Miguel A. Molina-Vila
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-24 (2023)
Abstract Background Drugs targeting the spindle assembly checkpoint (SAC), such as inhibitors of Aurora kinase B (AURKB) and dual specific protein kinase TTK, are in different stages of clinical development. However, cell response to SAC abrogation i
Externí odkaz:
https://doaj.org/article/0503e7da1cca40afa0953e96d2560af7
Autor:
Steven W. Criscione, Matthew J. Martin, Derek B. Oien, Aparna Gorthi, Ricardo J. Miragaia, Jingwen Zhang, Huawei Chen, Daniel L. Karl, Kerrin Mendler, Aleksandra Markovets, Sladjana Gagrica, Oona Delpuech, Jonathan R. Dry, Michael Grondine, Maureen M. Hattersley, Jelena Urosevic, Nicolas Floc’h, Lisa Drew, Yi Yao, Paul D. Smith
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-13 (2022)
Abstract Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an irreversible EGFR-TKI, are important treatments for non-small cell lung cancer with EGFR-TKI sensitizing or EGFR T790M resistance mutations. While patien
Externí odkaz:
https://doaj.org/article/d7852854a3ba43459578c3fb424140e2
Autor:
Clara Lassoudière
Publikováno v:
Critique d’art.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1810a8911804a9762b3c56590411c028
https://doi.org/10.4000/critiquedart.23477
https://doi.org/10.4000/critiquedart.23477
Autor:
Eric Tu, Kelly McGlinchey, Jixin Wang, Philip Martin, Steven L.K. Ching, Nicolas Floc’h, James Kurasawa, Jacqueline H. Starrett, Yelena Lazdun, Leslie Wetzel, Barrett Nuttall, Felicia S.L. Ng, Karen T. Coffman, Paul D. Smith, Katerina Politi, Zachary A. Cooper, Katie Streicher
Publikováno v:
JCI Insight, Vol 7, Iss 3 (2022)
Treatment with anti–PD-1 and anti-PD-L1 therapies has shown durable clinical benefit in non–small cell lung cancer (NSCLC). However, patients with NSCLC with epidermal growth factor receptor (EGFR) mutations do not respond as well to treatment as
Externí odkaz:
https://doaj.org/article/c6a5fda9646e49b8adcbb817d655948e
Autor:
Matthew J. Martin, Nicolas Floc'h, Matthias Pfeifer, Steven Criscione, Oona Delpuech, Sladjana Gagrica, Yi Yao, Ultan McDermott, Paul D. Smith
Publikováno v:
Cancer Research Communications. 2:1312-1325
Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with proven clinical efficacy; however, acquired resistance presents an obstacle to curing EGFR-driven disease. Recent studies have shown that drug-tolerant persister cells (DTP) have a distinct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15fea425209752f7335dbf2128f0fcac
https://doi.org/10.1158/2767-9764.crc-22-0066
https://doi.org/10.1158/2767-9764.crc-22-0066